{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:05:19Z","timestamp":1792649119725,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jconrel.2019.10.042","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T23:52:04Z","timestamp":1572652324000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Formulation Design, Optimization and In Vivo Evaluations of an \u03b1-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine"],"prefix":"10.1016","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-3671","authenticated-orcid":false,"given":"Rushit N.","family":"Lodaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey P.","family":"Kanitkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Henson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey P.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bertholet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M.","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jconrel.2019.10.042_bib0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrmicro2668","article-title":"The development of vaccines: how the past led to the future","volume":"9","author":"Plotkin","year":"2011","journal-title":"Nat Rev Microbiol."},{"key":"10.1016\/j.jconrel.2019.10.042_bib0010","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"1","article-title":"Overview of Vaccine Adjuvants: Introduction, History, and Current Status","author":"Shah","year":"2017"},{"issue":"Suppl 2","key":"10.1016\/j.jconrel.2019.10.042_bib0015","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants--from empiricism to rational design","volume":"33","author":"O\u2019Hagan","year":"2015","journal-title":"Vaccine."},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine Adjuvants: Putting Innate Immunity to Work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Review of Vaccines."},{"issue":"52","key":"10.1016\/j.jconrel.2019.10.042_bib0030","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine."},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/erv.09.5","article-title":"Emulsion-based adjuvants for influenza vaccines","volume":"8","author":"Vogel","year":"2009","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.jconrel.2019.10.042_bib0040","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-Adjuvanted Influenza Vaccines in Children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Frontiers in Immunology."},{"issue":"11","key":"10.1016\/j.jconrel.2019.10.042_bib0045","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.vaccine.2010.12.128","article-title":"Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets","volume":"29","author":"Baras","year":"2011","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev Vaccines."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.jconrel.2019.10.042_bib0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fimmu.2015.00207","article-title":"AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB\/c Mice","volume":"6","author":"Yam","year":"2015","journal-title":"Front Immunol."},{"issue":"13","key":"10.1016\/j.jconrel.2019.10.042_bib0065","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent h7n9 influenza vaccine with and without as03 and mf59 adjuvants on immune response: A randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.jconrel.2019.10.042_bib0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1377\/hlthaff.25.2.348","article-title":"The costs of scaling up vaccination in the world\u2019s poorest countries","volume":"25","author":"Bishai","year":"2006","journal-title":"Health Aff (Millwood)."},{"issue":"25","key":"10.1016\/j.jconrel.2019.10.042_bib0080","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med."},{"issue":"6088","key":"10.1016\/j.jconrel.2019.10.042_bib0085","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.1221466","article-title":"Influenza: options to improve pandemic preparation","volume":"336","author":"Rappuoli","year":"2012","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed Pharmacother."},{"issue":"5","key":"10.1016\/j.jconrel.2019.10.042_bib0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i5.10","article-title":"Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications","volume":"26","author":"Singh","year":"2009","journal-title":"Crit Rev Ther Drug Carrier Syst."},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0100","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jps.24337","article-title":"The Development of Self- Emulsifying Oil-in-Water Emulsion Adjuvant and an Evaluation of the Impact of Droplet Size on Performance","volume":"104","author":"Shah","year":"2015","journal-title":"Journal of Pharmaceutical Sciences."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ics.12119","article-title":"Formulation of tocopherol nanocarriers and in vitro delivery into human skin","volume":"36","author":"Abla","year":"2014","journal-title":"Int J Cosmet Sci."},{"issue":"1-2","key":"10.1016\/j.jconrel.2019.10.042_bib0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2004.05.016","article-title":"Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation","volume":"280","author":"Bouchemal","year":"2004","journal-title":"Int J Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2019.10.042_bib0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(00)00337-9","article-title":"Improved bioavailability of vitamin E with a self emulsifying formulation","volume":"200","author":"Julianto","year":"2000","journal-title":"Int J Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2019.10.042_bib0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.2042-7158.1984.tb04426.x","article-title":"Effect of formulation on the bioavailability of retinol, D-alpha- tocopherol and riboflavine","volume":"36","author":"Bateman","year":"1984","journal-title":"J Pharm Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2019.10.042_bib0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","article-title":"The applications of Vitamin E TPGS in drug delivery","volume":"49","author":"Guo","year":"2013","journal-title":"Eur J Pharm Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0130","first-page":"17","article-title":"MK, A. Shruti. Pharmaceutical profile of alpha-tocopherol - A brief review","volume":"1","author":"Waghmode","year":"2012","journal-title":"International Journal of Pharmaceutical and Chemical Sciences."},{"issue":"14","key":"10.1016\/j.jconrel.2019.10.042_bib0135","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jama.1953.02940140013005","article-title":"Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination","volume":"151","author":"Salk","year":"1953","journal-title":"J Am Med Assoc."},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1017\/S0022172400022610","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"Epidemiology and Infection."},{"issue":"1","key":"10.1016\/j.jconrel.2019.10.042_bib0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oxfordjournals.aje.a119500","article-title":"EVALUATION OF MONOVALENT INFLUENZA VACCINES: II. OBSEEVATION8 DUBING AN INFLUENZA A-PRIME EPIDEMIO1","volume":"55","author":"Meiklejohn","year":"1952","journal-title":"American Journal of Epidemiology"},{"issue":"36","key":"10.1016\/j.jconrel.2019.10.042_bib0150","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1016\/j.vaccine.2010.06.065","article-title":"Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6\u201335 months","volume":"28","author":"Carmona","year":"2010","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.jconrel.2019.10.042_bib0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/irv.12295","article-title":"Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination","volume":"9","author":"D\u00edez-Domingo","year":"2015","journal-title":"Influenza and other respiratory viruses."},{"issue":"29","key":"10.1016\/j.jconrel.2019.10.042_bib0160","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 \u2013 An innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ajcn\/52.3.557","article-title":"Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects","volume":"52","author":"Meydani","year":"1990","journal-title":"Am J Clin Nutr."},{"issue":"3","key":"10.1016\/j.jconrel.2019.10.042_bib0170","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S0029665199000919","article-title":"Vitamin E and infectious diseases in the aged","volume":"58","author":"Han","year":"1999","journal-title":"Proc Nutr Soc."},{"issue":"4","key":"10.1016\/j.jconrel.2019.10.042_bib0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3382\/ps.0740666","article-title":"Vitamin E in viral inactivated vaccines","volume":"74","author":"Franchini","year":"1995","journal-title":"Poult Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2019.10.042_bib0180","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3382\/ps.0701709","article-title":"Vitamin E as adjuvant in emulsified vaccine for chicks","volume":"70","author":"Franchini","year":"1991","journal-title":"Poult Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2019.10.042_bib0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-018-0058-4","article-title":"Activation of the endoplasmic reticulum stress sensor IRE1\u03b1 by the vaccine adjuvant AS03 contributes to its immunostimulatory properties","volume":"3","author":"Givord","year":"2018","journal-title":"npj Vaccines."},{"key":"10.1016\/j.jconrel.2019.10.042_bib0190","article-title":"Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators","author":"Lodaya","year":"2019","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"10.1016\/j.jconrel.2019.10.042_bib0195","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11095-009-9859-5","article-title":"MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)","volume":"26","author":"Baudner","year":"2009","journal-title":"Pharmaceutical Research."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:34:18Z","timestamp":1773178458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919306066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"alternative-id":["S0168365919306066"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.042","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation Design, Optimization and In Vivo Evaluations of an \u03b1-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}